Home | Life Sciences Intellectual Property Review
WEB4 days ago · The court rejected the medical device company’s auxiliary requests and nixed patent in 17 territories although it seems receptive to these amendments in general, say Laura Orlando and Rachel Montagnon of Herbert Smith Freehills.
Latest News & Features | Life Sciences Intellectual Property Review
WEBA request by CRISPR scientists to withdraw their patents over allegations of mishandling by the EPO’s Boards of Appeals has thrust a ‘fundamentally unfair, uncertain system’ into sharp focus, finds Sarah Speight.
Americas | Life Sciences Intellectual Property Review
WEB13 February 2024 US Patent and Trademark Office publishes ‘clear’ guidance mandating AI-related patents to have ‘significant’ human involvement | Cites one hypothetical example relating to the development of a compound for treating cancer | Kathi Vidal: ‘patent system was developed to incentivise and protect human ingenuity’.
Unified Patent Court | Life Sciences Intellectual Property Review
WEBA distinctive UPC approach to patent validity and revocations is emerging as the court shows its willingness to break new ground, say Emily Bottle and Sebastian Moore of HSF. Signs show that an uptick of life sciences cases at the Unified Patent Court is likely, but does the court have capacity ...
2024 forecast: AI, patent eligibility and Fintiv
WEBJan 2, 2024 · A few key items related to patents in the US are at the forefront of shaping our patent laws in 2024.
CRISPR | Life Sciences Intellectual Property Review
WEB9 November 2020 The European Patent Office has released the long-awaited reasoning for its decision to uphold the revocation of a Broad Institute CRISPR/Cas9 patent. In January this year, the EPO’s Board of Appeal concluded that the Broad’s patent, EP2,771,468, lacked novelty due to an invalid claim to priority.
UPC: life sciences lead the momentum at new court
WEBAug 15, 2023 · 26 September 2023 An updated UPC rule requires a concrete and verifiable, legitimate reason for making available written pleadings and evidence | The wish from a natural person to form an opinion on the validity of a patent deemed insufficient reason for access | First decision marks latest twist in Amgen v Sanofi showdown.
Moderna wins reprieve in COVID-19 vaccine dispute
WEB4 days ago · For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at [email protected]
The future of precision medicine part 1: challenges and …
WEBJun 13, 2018 · The promise of precision medicine has been extolled by researchers and clinicians for some time, but as sequencing costs continue to fall, sophistication of data analysis and patient stratification increases and data science and artificial intelligence (AI) begin to partner with the life sciences industry in earnest, that promise now seems closer than ever to realisation.
What does the UK’s pro-innovation approach to AI mean for life …
WEB13 February 2024 US Patent and Trademark Office publishes ‘clear’ guidance mandating AI-related patents to have ‘significant’ human involvement | Cites one hypothetical example relating to the development of a compound for treating cancer | Kathi Vidal: ‘patent system was developed to incentivise and protect human ingenuity’.